We sought to compare the efficacy of primary angioplasty in diabetics versus nondiabetics and to evaluate the relative benefits of angioplasty over thrombolytic therapy among diabetics.
Diabetes mellitus independently predicts morbidity and mortality after acute myocardial infarction (AMI) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Although thrombolytic therapy has improved outcomes among diabetics with AMI (16) , their outcomes remain unacceptably poor. The underlying mechanisms for these poor outcomes are not clearly understood; diabetics undergoing thrombolysis in the Global Utilization of Streptoki-nase and TPA (alteplase) for Occluded Coronary Arteries (GUSTO-I) study had similarly-sized or smaller infarctions compared with nondiabetics, similar 90-min patency rates, comparable 30-day reinfarction rates and equivalent left See page 1513 ventricular systolic function, yet their adjusted 30-day mortality was significantly higher (8) . However, vital information that could explain the worse outcome for diabetics is lacking. For example, there are few data on angiographic status before reperfusion therapy among diabetic and nondiabetic patients.
Primary angioplasty is an alternative strategy to achieve reperfusion in AMI (17) , but the effect of diabetic status on angiographic and clinical outcomes of this strategy have not been well documented. Primary angioplasty may be less successful among diabetics owing to the more extensive atherosclerosis, impaired microvascular autoregulation and prothrombotic and vasospastic effects of diabetes (2, 4) .
The Global Use of Strategies To Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb) Angioplasty Substudy is the largest randomized trial to compare primary angioplasty with accelerated thrombolysis using alteplase (18) . In this substudy, short-term outcomes were improved with primary angioplasty, and at six months the two strategies were comparable. The present analysis of the GUSTO-IIb Angioplasty Substudy cohort aimed to examine the impact of diabetic status on 1) the clinical and angiographic characteristics of patients before and after primary angioplasty and 2) the relative benefits of primary angioplasty versus thrombolysis for AMI.
METHODS
GUSTO-IIb angioplasty substudy. The main GUSTO-IIb trial was a prospective study of two adjunctive therapies, heparin or hirudin, in patients with acute coronary syndromes (19) . The GUSTO-IIb Angioplasty Substudy (18) also was designed to compare the efficacy of primary angioplasty versus alteplase for AMI. In brief, 1,138 patients from Europe, North America and Australia were enrolled prospectively from July 5, 1994, through January 1, 1996. Patients presenting within 12 h after symptom onset (chest pain lasting Ն20 min with ST segment elevation Ն2 mm in at least two contiguous leads or left bundle branch block) were eligible. Criteria for exclusion were previous stroke, active bleeding, contraindication to heparin, serum creatinine Ͼ 177 mol/L (Ͼ2.0 mg/dL), blood pressure Ͼ 200 mm Hg systolic or Ͼ 110 mm Hg diastolic, warfarin use at enrollment, ineligibility for angioplasty due to lack of arterial access site, childbearing potential and prior enrollment in GUSTO-II.
Eligible patients were randomized in a 2 ϫ 2 factorial design to either intravenous heparin (5,000-U bolus followed by a three-to five-day infusion at 1,000 U/h) or intravenous hirudin (0.1-mg/kg bolus followed by infusion at 0.1 mg/kg/h for three to five days) and either primary angioplasty or accelerated alteplase (15 mg intravenous bolus followed by an infusion of 0.75 mg/kg over 30 min, not to exceed 50 mg, then 0.50 mg/kg over the next hour, not to exceed 35 mg). Heparin and hirudin infusions were titrated to maintain an activated partial thromboplastin time (aPTT) of 60 to 85 s. All patients received aspirin (160 mg to be chewed at enrollment, followed by a daily dose of 80 to 325 mg); all other medications were given at the discretion of the attending physician.
Primary angioplasty was performed according to local standards, with the intent of reestablishing blood flow in the infarct artery as soon as possible. Heparin or hirudin was given after securing arterial access, but before angioplasty, at a dose titrated to reach an activated clotting time (ACT) Ն350 s. In general, the culprit artery was the only target. After intervention, the study drug was stopped temporarily to allow for sheath removal.
The Angiographic Core Laboratory analyzed cineangiograms with a validated edge-detection method (Artrek, version 1.69, Quinton Imaging Systems, Bothell, Washington) (20) . The following variables were recorded: pre-and post-treatment Thrombolysis In Myocardial Infarction (TIMI) flow grade, minimum luminal and reference diameter dimensions and percent diameter stenosis within the treated segment. Procedural success was defined as Ͻ50% residual diameter stenosis of the treated segment with TIMI grade 3 flow. (Antegrade flow into the coronary bed distal to the obstruction occurs as promptly as into the bed proximal to the obstruction, and clearance of the contrast material occurs as promptly as clearance of material from an uninvolved bed in the same vessel or opposite artery.) Extent of coronary artery disease before angioplasty was determined by the number of major epicardial arteries with Ն70% stenosis; multivessel disease was defined as Ն70% stenosis in at least two major epicardial arteries or Ն50% stenosis of the left main coronary artery.
Diabetes status.
Diabetes mellitus was considered present if a patient had been informed of this diagnosis and was on prescribed treatment (diet, tablets or insulin). In the study case report form, patients with diabetes mellitus were further categorized based on insulin/noninsulin treatment. Among the patients not receiving insulin, we did not record whether the treatment was diet alone or diet and tablets.
End points. The primary end point of the GUSTO-IIb Angioplasty Substudy (18) and of our analysis was a composite of overall death, nonfatal reinfarction or nonfatal, disabling stroke at 30 days, as confirmed by the clinical events committee. Reinfarction was confirmed by follow-up electrocardiogram and recurrent elevation of creatine kinase and creatine kinase-myocardial band levels. Computerized axial tomography or magnetic resonance imaging of the brain was recommended for all patients with suspected stroke. Ancillary end points included clinical event rates during hospitalization and at six and 12 months. The incidences of stroke and AMI were assessed only within the
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ACT ϭ activated clotting time AMI ϭ acute myocardial infarction aPTT ϭ activated partial thromboplastin time GUSTO-IIb ϭ Global Use of Strategies To Open Occluded Arteries in Acute Coronary Syndromes (trial)-IIb TIMI ϭ Thrombolysis In Myocardial Infarction first 30 days and 180 days, respectively. Procedural success, defined above, also was assessed among patients who were randomized to and underwent angioplasty. This substudy analysis was designed to detect a 40% relative reduction in the primary end point (30-day death, nonfatal reinfarction or nonfatal disabling stroke) with alpha ϭ 0.05 and beta ϭ 0.20 (or power ϭ 0.80).
Data analysis. All analyses were performed using SAS software (SAS Institute, Cary, North Carolina). Continuous variables were summarized as medians with 25th and 75th percentiles, and categorical variables as frequencies and percentages. Prespecified baseline variables were compared with the outcome variables of interest using chi-square tests for categorical variables (likelihood ratio chi-square or Fisher exact test and Cochran-Mantel-Haenszel test for stratified tables). Analysis of variance was used to compare the means of continuous variables, while the nonparametric Wilcoxon rank-sum test was used to compare the distributions of ranked outcomes. For both diabetic and nondiabetic groups, odds ratios with 95% confidence intervals were used to compare treatments with regard to the primary end point, under the intention-to-treat principle. Logistic regression modeling was used to assess the relationships of treatment assignment (angioplasty or alteplase) and diabetic status and their interaction (if any) with the primary end point. The baseline characteristics of interest are listed in Table 1 . Kaplan-Meier curves were also formulated to predict eventfree survival at six months (death or reinfarction) and at 12 months (death) for diabetic and nondiabetic patients, and the curves were compared using the log-rank statistic. All tests of significance were two-tailed. Differences between groups were considered significant at p Յ 0.05.
RESULTS
Of the 1,138 patients enrolled in the GUSTO-IIb Angioplasty Substudy, 177 were diabetic (of whom 78 were randomized to alteplase and 99 to angioplasty), and 961 were not diabetic (495 randomized to alteplase, 466 to angioplasty). The randomized diabetic group comprised 47 (27%) insulin-treated diabetics and 128 (73%) noninsulintreated diabetics. Two diabetic patients had missing diabetic treatment information.
Baseline demographic and clinical variables based on diabetic status. The diabetic patients were older, were more often women, weighed more and had a greater frequency of hypertension and peripheral vascular disease than nondiabetic patients (Table 1) . Baseline systolic blood pressure and heart rate were higher in diabetics. Current smoking was more common among nondiabetics. The times from symptom onset to hospital arrival, randomization and treatment (angioplasty or alteplase) were significantly longer for diabetics. In contrast, the time from arrival to treatment was similar for both groups, although diabetics had a slightly longer time to administration of alteplase after randomization than nondiabetics. The proportions of diabetic and nondiabetic patients randomized to heparin or hirudin were similar. The use of cardiac medications before and after randomization was similar between groups, except for a greater use before enrollment of beta-adrenergic blocking agents and angiotensin-converting enzyme inhibitors in diabetics ( Table 2) .
Angiographic variables.
Angiography was performed in 95 (96%) diabetics and 456 (98%) nondiabetics randomized to angioplasty. Of these, 21 had coronary angiography Ͼ6 h after enrollment: 4 (4.2%) diabetics and 17 (3.8%) nondiabetics. Eventually 81 (82%) diabetics and 391 (84%) nondiabetics underwent percutaneous intervention, of which only one (1.2%) diabetic and four (1%) nondiabetics underwent the procedure Ͼ6 h after enrollment. Thirteen patients randomized to coronary angioplasty were referred to coronary bypass graft surgery within 24 h of the coronary angiography.
In addition, 9 (9.1%) diabetic and 24 (5.2%) nondiabetic patients randomized to angioplasty received thrombolytic therapy. Ten of these patients underwent coronary angiography and received thrombolytic therapy, and 23 received thrombolytic therapy alone and did not undergo coronary angiography.
Of the patients randomized to alteplase, 74 (95%) diabetics and 477 (96%) nondiabetics received this or another thrombolytic agent. Angiography was later performed in 53 (68%) diabetics and 305 (62%) nondiabetics, and 20 (26%) diabetics and 110 (22%) nondiabetics underwent intervention. Angiography was performed within 6 h of enrollment in 7 (14%) diabetics and 44 (16%) nondiabetics randomized to alteplase.
Among the patients randomized to angioplasty who underwent angiography, multivessel disease was more prevalent in diabetics than it was in nondiabetics (p ϭ 0.06, Table 3 ). Left ventricular ejection fraction also was significantly lower in diabetics (p ϭ 0.003). The minimum luminal diameter was smaller in diabetics (p ϭ 0.07), as was the reference-segment diameter (p ϭ 0.08), resulting in a greater percent diameter stenosis among diabetics (p ϭ 0.054). Although the distribution of initial TIMI flow grades did not differ significantly between diabetics and nondiabetics, 80.7% of diabetics had TIMI grade 0 or 1 flow compared with 71.8% of nondiabetics (p ϭ 0.10). There was no difference in culprit-artery distribution between groups.
Among the patients randomized to and undergoing intervention, multivessel disease was more prevalent in diabetics than it was in nondiabetics (p ϭ 0.01, Table 4 ). Left ventricular ejection fraction also was lower in diabetics (p ϭ 0.051). The minimum luminal diameter was smaller in diabetics (p ϭ 0.06), as was the reference-segment diameter (p ϭ 0.06), resulting in a greater percent diameter stenosis among diabetics (p ϭ 0.09). A greater proportion of diabetics than nondiabetics had TIMI grade 0 or 1 flow before intervention (84% and 76%, respectively; p ϭ 0.12).
There was no difference in culprit-artery distribution between groups. Balloon angioplasty alone was the major modality used in both groups, and the procedure was equally successful for diabetics and nondiabetics (success rates of 70.4% and 72.4%, respectively; p ϭ 0.79). Femoral vascular bleeding complications were also similarly uncommon (p ϭ 0.98).
Of the patients randomized to angioplasty who under- 
Coagulation variables.
Maximum ACT values during angioplasty did not differ significantly between groups (Table  6 ). In addition, aPTTs for patients randomized to and undergoing angioplasty were similar at all intervals within 48 h for diabetics and nondiabetics. The aPTT values among nondiabetics randomized to alteplase were higher at 6 h and 48 h.
In-hospital outcomes. The frequency of major in-hospital adverse outcomes was similar for diabetics and nondiabetics, regardless of treatment strategy ( Table 7) , except that both in-hospital heart failure and cardiogenic shock were more common among diabetics (p ϭ 0.001 and p ϭ 0.04, respectively). Diabetic patients undergoing angioplasty had a significantly greater incidence of bleeding complications compared with those receiving thrombolytic therapy. Reperfusion by angioplasty was associated with a significant reduction in the occurrence of in-hospital recurrent ischemia compared with alteplase for both diabetics (13.1% vs. 29.5%, p ϭ 0.007) and nondiabetics (14.1% vs. 23.1%, p Ͻ 0.001). There was a significant interaction between diabetic status and treatment strategy with respect to the occurrence of in-hospital recurrent ischemia (p Ͻ 0.001). There was also an interaction between diabetic status and treatment strategy on in-hospital refractory ischemia, although it did not reach statistical significance (p ϭ 0.07). The duration of hospital stay for diabetics did not differ after either alteplase or angioplasty, but nondiabetic patients spent a median one less day in the hospital after angioplasty versus alteplase (p ϭ 0.0001).
30-day outcomes.
For the whole population, the composite 30-day outcome occurred less often with angioplasty than with alteplase, irrespective of diabetic status (p ϭ 0.03, Table 8 ). Primary angioplasty also was associated with better overall adjusted outcome (adjusted odds ratio, 0.63; 95% confidence interval, 0.43-0.93). The composite 30-day end point of death, nonfatal reinfarction or nonfatal, disabling stroke was reached in 24 of 171 diabetics (13.6%) and in 108 of 961 nondiabetics (11.2%; adjusted odds ratio, Six-month death/reinfarction. Within six months of follow-up after AMI (Fig. 1) , there was no significant differ-ence in the cumulative incidence of death/reinfarction between diabetic and nondiabetic patients (p ϭ 0.18 using the log-rank statistic). Among the diabetic patients, there was no difference between those randomized to angioplasty versus thrombolytic therapy (p ϭ 0.48), with a similar trend for nondiabetics (p ϭ 0.52). Among patients who had TIMI 3 flow post-angioplasty, there was no difference in six-month survival free of death/ reinfarction between diabetics and nondiabetics (estimated event-free survival of 0.93 Ϯ 0.03 and 0.91 Ϯ 0.02, respectively; p ϭ 0.55). Likewise, six-month event-free survival was similarly poor for patients who did not achieve TIMI 3 flow (estimated event-free survival of 0.75 Ϯ 0.08 and 0.83 Ϯ 0.04, respectively; p ϭ 0.33). 12-month survival. Mortality within 12 months after AMI (Fig. 2) was marginally higher among diabetic than nondiabetic patients (p ϭ 0.09). After adjusting for differences in baseline variables, the odds ratio of death within 12 months for diabetics was 1.34 (95% confidence interval, 0.78 -2.31). Mortality within 12 months was not significantly different among both diabetics and nondiabetics randomized to angioplasty compared with alteplase (p ϭ 0.95 and p ϭ 0.47, respectively, using the log-rank statistic). Among patients who had TIMI 3 flow post-angioplasty, there was no difference in 12-month survival between diabetics and nondiabetics (estimated survival of 0.98 Ϯ 0.02 and 0.95 Ϯ 0.01, respectively; p ϭ 0.90). Likewise, 12-month survival was similarly poor for patients who did not achieve TIMI 3 flow (estimated survival of 0.77 Ϯ 0.08 and 0.86 Ϯ 0.03, respectively; p ϭ 0.25).
Diabetic treatment strategy and outcome. Of the 78 diabetic patients who were randomized to alteplase, 22 were insulin-treated and 55 were treated by diet with or without tablets (one patient had unknown treatment status). The primary end point was reached in 18.2% and 14.6% of insulin-and noninsulin-treated patients, respectively (p ϭ NS). Of the 99 diabetic patients randomized to angioplasty, 25 were insulin-treated and 73 were treated by diet with or without tablets (one patient had unknown treatment status). The primary end point was reached in 4.0% and 13.7% of insulin-and noninsulin-treated patients, respectively (p ϭ NS). We did not find an interaction between diabetic treatment strategy and reperfusion strategy (alteplase vs. angioplasty) with respect to outcome.
DISCUSSION
The principal finding of this analysis from the GUSTO-IIb Angioplasty Substudy was that outcomes in-hospital, at 30 days and at 6 and 12 months were better among diabetics randomized to primary angioplasty compared with those randomized to accelerated alteplase. Despite the worse clinical and angiographic profiles of diabetics upon presentation, primary angioplasty was similarly successful among diabetics and nondiabetics. Therefore, similar to patients without diabetes, this strategy should be contemplated as an alternative reperfusion strategy for diabetics presenting with AMI.
Diabetes and factors before reperfusion therapy. Our study highlights two important pretreatment factors that may partly explain the worse outcomes of diabetics reported in prior studies. The first, the significant delay from symptom onset to hospital arrival, results in a significant delay in the administration of reperfusion treatment. This has been reported in other trials (7,8,20 -22) and may partially reflect the difficulty in interpreting the electrocardiograms of diabetic patients, who frequently have complex coronary artery disease. In addition, the presenting symptoms of diabetic patients may be more difficult to relate to active ischemic heart disease. The second factor is the significantly worse angiographic features of the culprit artery before reperfusion therapy. Current knowledge about the effect of diabetes on the angiographic characteristics of patients with AMI is based primarily on data derived from trials in which angiography was performed after thrombolysis. Our data are unique in that angiography was performed before reperfusion therapy in a large proportion of patients. Our findings show that before reperfusion treatment, diabetics have a higher incidence of TIMI grade 0 or 1 flow and more severe stenosis of the culprit artery than do nondiabetics.
Several possible mechanisms may explain the relatively greater stenosis of the culprit artery and worse flow among diabetics before reperfusion therapy. First, as mentioned above, there are significant delays until hospital arrival and treatment among diabetics. Thus, by the time reperfusion therapy is contemplated for diabetics, the occluding thrombus may be in advanced stages of organization. In addition, diabetics have increased platelet aggregatory and procoagulant activity, leading to an inherently greater incidence and rate of thrombus formation (2, 11) . The dynamic balance between thrombosis and endogenous fibrinolysis probably is shifted toward accelerated thrombosis in diabetics (4, 11) , possibly due to 1) the enhanced activation, adhesion and aggregation of platelets, 2) elevated levels of circulating procoagulant factors (such as fibrinogen, von Willebrand factor, Factor VII) and 3) impaired endogenous fibrinolysis secondary to elevation in plasminogen activator inhibitor-1 
